Literature DB >> 1804092

The role of hysteroscopy in patients having failed IVF/GIFT transfer cycles.

R Kirsop1, R Porter, H Torode, D Smith, D Saunders.   

Abstract

Fifty patients who had undergone 2 or more failed in vitro fertilization (IVF) embryo transfer (ET) cycles or failed GIFT cycles where fertilization had been demonstrated, underwent hysteroscopy; 28% were found to have intrauterine abnormalities which may have been responsible for the failure of the IVF-ET or GIFT. Patients with an abnormality found at hysteroscopy had undergone a significantly higher mean number of transfer cycles. These results suggest that intrauterine abnormalities may be a cause for failure of IVF-ET or GIFT and therefore hysteroscopy should be part of the infertility work-up of all patients prior to undergoing IVF treatment.

Entities:  

Mesh:

Year:  1991        PMID: 1804092     DOI: 10.1111/j.1479-828x.1991.tb02795.x

Source DB:  PubMed          Journal:  Aust N Z J Obstet Gynaecol        ISSN: 0004-8666            Impact factor:   2.100


  4 in total

1.  "Chromohysteroscopy" for evaluation of endometrium in recurrent in vitro fertilization failure.

Authors:  Tansu Küçük; Mukerrem Safali
Journal:  J Assist Reprod Genet       Date:  2008-01-29       Impact factor: 3.412

2.  Role of hysteroscopy prior to assisted reproductive techniques.

Authors:  Nandita Palshetkar; Hrishikesh Pai; Suchita Pisat
Journal:  J Gynecol Endosc Surg       Date:  2009-01

3.  Hysteroscopic findings in patients with a history of two implantation failures following in vitro fertilization.

Authors:  Ashraf Moini; Kiandokht Kiani; Firouzeh Ghaffari; Fatemeh Hosseini
Journal:  Int J Fertil Steril       Date:  2012-06-19

4.  A multi-centre randomised controlled study of pre-IVF outpatient hysteroscopy in women with recurrent IVF implantation failure: Trial of Outpatient Hysteroscopy - [TROPHY] in IVF.

Authors:  Tarek El-Toukhy; Rudi Campo; Sesh Kamal Sunkara; Yacoub Khalaf; Arri Coomarasamy
Journal:  Reprod Health       Date:  2009-12-03       Impact factor: 3.223

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.